Income Statement
ENANTA PHARMACEUTICALS INC
ENTA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Sep 30, 2025 2025 FY | Sep 30, 2024 2024 FY | Sep 30, 2023 2023 FY | Sep 30, 2022 2022 FY | Sep 30, 2021 2021 FY | Sep 30, 2020 2020 FY | Sep 30, 2019 2019 FY | Sep 30, 2018 2018 FY | Sep 30, 2017 2017 FY | Sep 30, 2016 2016 FY | Sep 30, 2015 2015 FY | Sep 30, 2014 2014 FY | Sep 30, 2013 2013 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
65.32 | 67.64 | 79.20 | 86.16 | 97.07 | 122.47 | 205.20 | 206.63 | 102.81 | 88.27 | 160.88 | 47.74 | 32.05 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
65.32 | 67.64 | 79.20 | 86.16 | 97.07 | 122.47 | 205.20 | 206.63 | 102.81 | 88.27 | 160.88 | 47.74 | 32.05 |
|
Operating Expenses
|
150.67 | 189.33 | 216.41 | 210.00 | 206.65 | 164.11 | 168.46 | 118.30 | 78.20 | 57.43 | 36.73 | 28.76 | 23.02 |
|
Research & Development
|
106.74 | 131.48 | 163.52 | 164.52 | 174.11 | 136.76 | 142.21 | 94.86 | 57.45 | 40.46 | 23.19 | 18.74 | 16.84 |
|
Selling, General & Administrative
|
43.93 | 57.85 | 52.89 | 45.48 | 32.54 | 27.36 | 26.25 | 23.44 | 20.75 | 16.97 | 13.54 | 10.02 | 6.18 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-85.35 | -121.69 | -137.21 | -123.84 | -109.57 | -41.64 | 36.74 | 88.33 | 24.61 | 30.84 | 124.15 | 18.99 | 9.03 |
|
Non-Operating Income
|
1.80 | 3.90 | 6.21 | 1.66 | 1.99 | 6.62 | 8.82 | 4.79 | 2.33 | 1.72 | 1.31 | 0.28 | 0.60 |
|
Interest Income
|
- | - | - | - | - | - | - | - | 2.53 | 1.74 | 0.97 | 0.47 | 0.25 |
|
Interest Expense
|
8.20 | 0.67 | 5.15 | - | - | - | - | - | 0.04 | 0.05 | 0.01 | 0.02 | 0.03 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
Income Before Tax
|
-83.55 | -117.79 | -131.00 | -122.19 | -107.58 | -35.02 | 45.56 | 93.12 | 26.95 | 32.56 | 125.46 | 19.27 | - |
|
Income Tax Expense
|
-1.66 | -1.74 | 2.82 | -0.43 | -28.58 | 1.15 | -0.83 | 21.17 | 9.24 | 10.89 | 46.46 | -15.17 | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-81.89 | -116.05 | -133.82 | -121.76 | -79.00 | -36.17 | 46.38 | 71.96 | 17.71 | 21.67 | 78.99 | 34.44 | 9.63 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Sep 30, 2025 2025 FY | Sep 30, 2024 2024 FY | Sep 30, 2023 2023 FY | Sep 30, 2022 2022 FY | Sep 30, 2021 2021 FY | Sep 30, 2020 2020 FY | Sep 30, 2019 2019 FY | Sep 30, 2018 2018 FY | Sep 30, 2017 2017 FY | Sep 30, 2016 2016 FY | Sep 30, 2015 2015 FY | Sep 30, 2014 2014 FY | Sep 30, 2013 2013 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-80.76 | -119.36 | -134.84 | -120.87 | -106.24 | -38.00 | 40.00 | 90.85 | 26.75 | 32.50 | 124.79 | 19.34 | 9.25 |
|
Earnings Per Share (Basic)
|
-3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.74 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 |
|
Diluted EPS
|
-3.84 | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 |
|
Weighted Average Shares
|
0.02 | 0.02 | 0.02 | 0.02 | 20.17 | 19.94 | 19.58 | 19.26 | 19.07 | 0.02 | 18.67 | 18.35 | 9.79 |
|
Diluted Weighted Avg Shares
|
0.02 | 0.02 | 0.02 | 0.02 | 20.17 | 19.94 | 20.97 | 20.65 | 19.41 | 0.02 | 19.29 | 19.19 | 9.79 |
|
Comprehensive Income
|
-82.53 | -114.57 | -131.27 | -125.10 | -80.22 | -35.47 | 46.93 | 71.67 | 17.58 | 21.65 | 79.13 | 34.34 | 9.62 |